NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $48.41 -0.79 (-1.61%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AnaptysBio Stock (NASDAQ:ANAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AnaptysBio alerts:Sign Up Key Stats Today's Range$49.20▼$49.2050-Day Range$48.53▼$59.6952-Week Range$19.65▼$72.36Volume1,307 shsAverage Volume689,678 shsMarket Capitalization$1.45 billionP/E Ratio9.06Dividend YieldN/APrice Target$77.79Consensus RatingModerate Buy Company Overview AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis. Its development programs and priorities may change as clinical studies progress. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also pursued collaborations and licensing arrangements with larger pharmaceutical companies. Historically, antibodies discovered using the company’s technology have contributed to programs such as dostarlimab, an immune checkpoint inhibitor subsequently developed and commercialized by another company. AnaptysBio is led by President and Chief Executive Officer Hamid Tabatabai.AI Generated. May Contain Errors. Read More AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreANAB MarketRank™: AnaptysBio scored higher than 72% of companies evaluated by MarketBeat, and ranked 170th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAnaptysBio has a consensus price target of $77.79, representing about 58.1% upside from its current price of $49.20.Amount of Analyst CoverageAnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($1.30) to $1.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is 9.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is 9.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 36.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AnaptysBio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.81% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 10.25, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 0.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.12 News SentimentAnaptysBio has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for AnaptysBio this week, compared to 6 articles on an average week.Search Interest3 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,350.00 in company stock.Percentage Held by Insiders31.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAnaptysBio has minimal institutional ownership at this time.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Stock News HeadlinesAnaptysBio (NASDAQ:ANAB) Cut to Hold at Wall Street ZenOctober 4 at 1:07 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Director Hollings Renton Sells 5,000 Shares of Company StockOctober 3 at 5:38 AM | americanbankingnews.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 6 at 1:00 AM | Porter & Company (Ad)AnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of StockOctober 3 at 5:37 AM | insidertrades.comJPMorgan Chase & Co. Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock PriceOctober 2, 2026 | americanbankingnews.comAnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash PerformanceSeptember 26, 2026 | finance.yahoo.comAnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?September 26, 2026 | insidermonkey.comWhat is HC Wainwright's Forecast for AnaptysBio Q3 Earnings?September 26, 2026 | americanbankingnews.comSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $48.48 at the beginning of 2026. Since then, ANAB stock has increased by 1.5% and is now trading at $49.20. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) issued its earnings results on Monday, September, 21st. The biotechnology company reported $5.11 EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $5.58. The biotechnology company earned $27.49 million during the quarter, compared to the consensus estimate of $14.06 million. AnaptysBio had a net margin of 82.37% and a trailing twelve-month return on equity of 112.00%. Is AnaptysBio buying back stock? AnaptysBio's Board of Directors authorized a stock repurchase program on Friday, March 27th 2026, which authorizes the company to buy back $100,000,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $75 million in an IPO on Thursday, January 26th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG). Company Calendar Last Earnings9/21/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANAB's financial health is in the Green zone, according to TradeSmith. ANAB has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees104Year Founded2005Price Target and Rating Average Price Target for AnaptysBio$77.79 High Price Target$100.00 Low Price Target$50.00 Potential Upside/Downside+60.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$5.37 Trailing P/E Ratio9.06 Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.23 million Net Margins82.37% Pretax Margin-11.46% Return on Equity112.00% Return on Assets2.20% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$232.39 million Price / Sales6.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book36.12Miscellaneous Outstanding Shares29,895,000Free Float20,478,000Market Cap$1.45 billion OptionableOptionable Beta0.76 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ANAB) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
